Life science VCs driving AI innovation: the view from the interface in 2025

As AI becomes an increasingly ubiquitous part of daily life, the longstanding question of its impact on drug development is less “whether” than “how.” VC firms that have made this question a core part of their thesis are meeting the moment with different strategies, ranging from providing centralized resources, to funding critical infrastructure, to keeping a narrow focus on practical questions while staying cautious about the hype. 

These days, it’s difficult to find a biopharma VC that views AI as irrelevant to their portfolio, but a smaller subset of firms have made the technology a central part of their raison d’être, either from inception, or within the last few years...